At Stock Day Media, we’re highlighting plant-based natural health ingredient and product company, Panacea Life Sciences Holdings, Inc. (OTCQB:PLSH). As a leader in the cannabinoid research and development space with plans to expand into the growing mushroom market, investors will want to learn more about this uniquely positioned company below.
About Panacea Life Sciences Holdings, Inc.
Operating out of its 51,000 square foot, state-of-the-art, cGMP facility in Golden Colorado since 2019, Panacea Life Sciences Holdings, Inc. is a holding company structured to develop and facilitate manufacturing, research, product development and distribution in the high-growth, natural human and animal health & wellness market segment. Its subsidiary, Panacea Life Sciences, Inc. (PLS) is a woman-founded and led company, by CEO Leslie Buttorff, dedicated to manufacturing, distribution, research and the production of the highest-quality nutraceutical, cannabinoid, mushroom, kratom and other natural, plant-based ingredients and products.
Panacea Life Sciences is currently in the process of acquiring eight retail locations in Tampa, Florida with a long-term goal to own and or operate hundreds of stores that offer Kava Kratom, CBD, mushroom and vape products. This includes an expansion into both Mexico and Europe as the global demand for natural health and wellness products continues to increase.
Growing Pipeline of Natural Wellness Products
In 2019, Panacea Life Sciences Holdings, Inc. founded the Cannabinoid Research Center located at Colorado State University, while also acquiring Needlerock farms, a 250-acre hemp farm, located in Crawford, CO to increase quality of hemp supply as well as gain access to unique genetics. In 2020, Panacea received its full GMP certification and made the strategic shift from a CBD to cannabinoid company, allowing them to concentrate and purify each cannabinoid produced in the hemp plant.
In 2023, Panacea now has a full pipeline of products, including:
These product lines feature expertly formulated softgels, tablets, topicals, tinctures, and edibles, as well as skin care and pet options. However, Panacea’s pipeline of meticulously researched products continues to grow.
Mushroom Market Expansion
Led by Chief Science Officer, Dr. James Baumgartner, Panacea Life Sciences is also facilitating research and development for the mushroom market with the goal to provide new products to help individuals around the world with specific conditions or needs through dietary supplements. Currently, the mushroom market is divided into three unique segments, including functional mushrooms, psilocybin mushrooms, and Amanita Muscaria mushrooms. Active ingredients associated with these mushroom segments may offer a wide range of health benefits, including improved memory, immune function, gut health, and exercise performance and endurance. For Panacea Life Sciences, this represents a significant opportunity to further expand its product offerings and capabilities in an evolving market.
Learn More About Panacea Life Sciences Holdings, Inc. Today!
Despite Panacea’s proven record for growth, the company continues to remain undervalued, representing a significant opportunity for investors. With a market cap of just over $6 million dollars and a stock price of 0.4 cents, which is projected to reach $2 within the next six months by Stock Day Media, investors are encouraged to learn more about Panacea Life Sciences Holdings, Inc., here. For more information about Panacea and their upcoming projects and announcements, visit StockDayMedia.com.